U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Approvals and Databases
  5. Drug Trials Snapshots: BESREMi
  1. Drug Approvals and Databases

Drug Trials Snapshots: BESREMi

HOW TO USE THIS SNAPSHOT
The information provided in Snapshots highlights who participated in the key clinical trials that supported the original FDA approval of this drug, and whether there were differences among sex, race, age, and ethnic groups. The “MORE INFO” bar shows more detailed, technical content for each section. The Snapshot is intended as one tool for consumers to use when discussing the risks and benefits of the drugs.

LIMITATIONS OF THIS SNAPSHOT
Do not rely on Snapshots to make decisions regarding medical care. Always speak to your healthcare provider about the benefits and risks of a drug.

Some of the information in this Snapshot is for presentation purposes and does not represent the approved conditions of use of this drug. Refer to the BESREMi Prescribing Information (USPI for BESREMi®) for all of the approved conditions of use of this drug (e.g., indication(s), population(s), dosing regimen(s), safety information).

Snapshots are limited to the information available at the time of the original approval of the drug and do not provide information on who participated in clinical trials that supported later approvals for additional uses of the drug (if applicable).

BESREMi (ropeginterferon alfa-2b-njft) injection
(bez-reh-me)
PharmaEssentia Corporation
Approval date: November 12, 2021


DRUG TRIALS SNAPSHOT SUMMARY:

What is the drug for?

BESREMi is an interferon alfa-2b drug used to treat adults with polycythemia vera, a blood disease that causes the overproduction of red blood cells. The excess cells thicken the blood, slowing blood flow and increasing the chance of blood clots.

How is this drug used?

How is this drug used? BESREMi is an injection that is given under the skin (subcutaneously) every three weeks. The starting dosage may differ for adults with polycythemia vera who are not on hydroxyurea or transitioning from hydroxyurea, known as the titration phase (refer to the BESREMi Prescribing Information: USPI for BESREMi®).

Who participated in the clinical trials?

The FDA approved BESREMi based on evidence from a clinical trial of 51 patients with polycythemia vera. The trial was conducted at six sites exclusively in Austria. The safety of BESREMi was based primarily on findings from the efficacy study in 51 patients. Two additional studies served as supportive safety data; therefore, the number of patients representing efficacy findings may differ from the number of patients representing safety findings due to different pools of study participants analyzed for efficacy and safety.

What are the benefits of this drug?

BESREMi works to normalize blood counts, spleen size, and prevent new blood clots. In the trial, 61% of patients receiving BESREMi achieved this benefit (see the BESREMi Prescribing Information: USPI for BESREMi®).

Were there any differences in how well the drug worked in clinical trials among sex, race and age?

  • Sex: BESREMi worked similarly in female and male subjects regarding complete hematological response (CHR). More male subjects were treated and completed the study than female subjects.
  • Race: The number of patients of races other than White was very small; therefore, differences in how BESREMi worked among races could not be determined.
  • Age: BESREMi worked similarly in patients below and above 65 years of age regarding CHR.

What are the possible side effects?

BESREMi can cause serious side effects including urinary tract infection, transient ischemic attack, and depression. BESREMi may cause harm to unborn babies. The most common side effects of BESREMi are liver enzyme elevation, leukopenia, thrombocytopenia, arthralgia, fatigue, myalgia, and influenza-like illness. Monitor complete blood count more frequently if clinically indicated. Phlebotomy as rescue treatment to normalize blood hyperviscosity may be necessary during the titration phase.

Warnings and Precautions listed below have occurred in patients receiving products similar to BESREMi, some of which were identified during the use of BESREMi. They include depression and suicide, endocrine toxicity, cardiovascular toxicity, decreased peripheral blood counts, pancreatitis, ophthalmologic toxicity, hyperlipidemia, liver and renal toxicities (USPI for BESREMi®).

Were there any differences in side effects among sex, race and age?

  • Sex: The rate of side effects from BESREMi was similar in both females and males. The rate of Grade 3 or higher side effects from BESREMi was slightly larger among females.
  • Race: The number of patients of races other than White was small; therefore, differences among races in the rate of side effects from BESREMi could not be determined
  • Age: The rate of side effects was slightly larger in the >=65-year-old age group compared to the 18–64-year-old group. >=65-year-old age group.

DEMOGRAPHICS SNAPSHOT

Figure 1 summarizes how many male and female patients were enrolled in the clinical trials used to evaluate the efficacy of BESREMi.

Figure 1. Baseline Demographics by Sex (Efficacy Population)

Pie chart summarizing how many male and female patients were in the clinical trial. In total, 31 (61%) male patients and 20 (39%) female patients participated in the clinical trial.

Source: Adapted from FDA Review

Figure 2 summarizes how many patients by sex were in the combined trials used to evaluate the side effects of BESREMi.

Figure 2. Baseline Demographics by Sex (Safety Population)

Pie chart summarizing how many male and female patients were in the clinical trial. In total, 90 (49%) male patients and 88 (51%) female patients participated in the clinical trial.

Source: Adapted from FDA Review

Figure 3 summarizes the percentage of patients by race enrolled in the clinical trial used to evaluate the efficacy of BESREMi.

Figure 3. Baseline Demographics by Race (Efficacy Population)

Pie chart summarizing how many White, Black, Asian, and other patients were in the clinical trial. In total, 50 (98%) White patients and 1 (2%) Asian patients participated in the clinical trial.

Source: Adapted from FDA Review

Figure 4 summarizes how many patients by race were in the combined trials used to evaluate the side effects of BESREMi.

Figure 4. Baseline Demographics by Race (Safety Population)

Pie chart summarizing how many White, Black, Asian, and other patients were in the clinical trial. In total, 177 (99%) White patients and 1 (1%) Asian patients participated in the clinical trial.

Source: Adapted from FDA Review

Figure 5 summarizes the percentage of patients by age group enrolled in the clinical trial used to evaluate the efficacy of BESREMi.

Figure 5. Baseline Demographics by Age (Efficacy Population)

Pie chart summarizing how many patients by age were in the clinical trial. In total, 30 (58%) patients were between the age of 18 and 64 years of age and 21 (42%) patients were 65 years and older that participated in the clinical trial.

Source: Adapted from FDA Review

Figure 6 summarizes the percentage of patients by age group enrolled in the combined trials used to evaluate the side effects of BESREMi.

Figure 6. Baseline Demographics by Age (Safety Population)

Pie chart summarizing how many patients by age were in the clinical trial. In total, 124 (70%) patients were between the age of 18 and 64 years of age and 54 (30%) patients were 65 years and older that participated in the clinical trial.

Source: Adapted from FDA Review

How were the trials designed?

BESREMi was evaluated in one clinical trial of 51 patients with polycythemia vera. In the trial, patients received the highest administered dose tolerated every two weeks subcutaneously. The starting dose was lower for patients who were transitioning from hydroxyurea.

The benefit of BESREMi was assessed by the proportion of patients who achieved normal blood counts, normal spleen size, and no new blood clots.

GLOSSARY

CLINICAL TRIAL: Voluntary research studies conducted in people and designed to answer specific questions about the safety or effectiveness of drugs, vaccines, other therapies, or new ways of using existing treatments.
COMPARATOR: A previously available treatment or placebo used in clinical trials that is compared to the actual drug being tested.
EFFICACY: How well the drug achieves the desired response when it is taken as described in a controlled clinical setting, such as during a clinical trial.
PLACEBO: An inactive substance or “sugar pill” that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.
SUBGROUP: A subset of the population studied in a clinical trial. Demographic subsets include sex, race, and age groups.

PRESCRIBING INFORMATION

Back to Drug Trials Snapshots

Back to Top